ClinicalTrials.gg
CompletedNCT01460342Updated Sep 25, 2013Results posted

Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)

A Phase 3 interventional study of Tadalafil and Placebo in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 17 sites in 2 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2013-09-25.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
610
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.

Enrollment
5th of 26
610 · median 258
Started
2011
the only one that year
Phase 3
10 of 26
none open now
Registered
14th of 26
by date
Lead sponsor
16 of 26
Eli Lilly and Company

Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 5th largest by enrollment, is the only one that started in 2011, is one of 10 in phase 3, and was the 14th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tadalafil in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

This is a phase 3, randomized, double-blind, placebo-controlled, parallel-design, multinational study to evaluate the efficacy and safety of tadalafil once-a-day dosing for 12 weeks in Asian men with signs and symptoms of benign prostatic hyperplasia.

Read the detailed description

Tadalafil is being investigated as a treatment for men with signs and symptoms of benign prostatic hyperplasia [BPH; also referred to as urinary disturbance or BPH-LUTS (BPH-lower urinary tract symptoms)] in Japan and overseas. Overseas studies and the Japanese dose-finding study LVIA (NCT00783094) identified tadalafil 5 mg once-daily as the recommended dose. The long-term safety and maintenance of effect was confirmed in the open-label extension of study LVIA. The risk-benefit profile was further studied in the Asian study LVHB (NCT00861757).

This study, LVJF, is to confirm the efficacy and safety of tadalafil 5 mg once-daily in Asian men with BPH-LUTS.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

Keywords

  • Prostatic hyperplasia
  • Benign prostatic hyperplasia
  • Lower urinary tract
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present with benign prostatic hyperplasia (BPH; also referred to as BPH-LUTS), based on the disease diagnostic criteria, at study entry.
  • Provide signed at study entry.
  • Have BPH-LUTS with a Total International Prostate Symptom Score (IPSS) of ≥13 at beginning of placebo lead-in period.
  • Have bladder outlet obstruction of intermediate severity as defined by a urinary peak flow rate (Qmax) of ≥4 to ≤15 milliliters per second (mL/sec) [from a prevoid total bladder volume (assessed by ultrasound) of ≥150 to ≤550 milliliters (mL) and a minimum voided volume of 125 mL] at beginning of placebo lead-in period.
  • Have prostate volume ≥20 mL estimated by transabdominal or transrectal ultrasound at study entry.
  • Agree not to use any other approved or experimental pharmacologic BPH, erectile dysfunction (ED) and/or overactive bladder (OAB) treatments, including alpha-blockers, 5-alpha reductase inhibitors (5-ARIs), phosphodiesterase type 5 (PDE5) inhibitors, or herbal preparations at any time during the study.
  • Have not taken the following treatments within the indicated duration:

    • Finasteride therapy for at least 3 months prior to beginning of placebo lead-in period.
    • Dutasteride therapy for at least 6 months prior to beginning of placebo lead-in period.
    • Anti-androgenic hormone therapy at least 12 months prior to beginning of placebo lead-in period.
    • All other BPH therapy (including herbal preparations) for at least 4 weeks prior to beginning of placebo lead-in period.
    • ED therapy for at least 4 weeks prior to beginning of placebo lead-in period.
    • OAB therapy for at least 4 weeks prior to beginning of placebo lead-in period.
  • Demonstrate compliance with study drug administration requirements during the placebo lead-in period by administering ≥70% of prescribed doses, confirmed by documentation that the participant returned ≤30% of prescribed doses at randomization.

Exclusion criteria

Exclusion Criteria:

  • Prostate-specific antigen (PSA) >10.0 nanograms per milliliter (ng/mL) at study entry.
  • PSA ≥4.0 to ≤10.0 ng/mL at study entry, if prostate has not been ruled out to the satisfaction of an urologist.
  • Bladder postvoid residual (PVR) ≥300 mL by ultrasound determination at study entry.
  • History of any of the following pelvic conditions (checked at study entry):

    • Pelvic surgery or any other pelvic procedure, including radical prostatectomy, pelvic surgery for removal of malignancy, or bowel resection.
    • Pelvic radiotherapy.
    • Any pelvic surgical procedure on the urinary tract, including minimally invasive BPH-LUTS therapies and penile implant surgery.
    • Lower urinary tract malignancy or trauma.
  • Lower urinary tract instrumentation (including prostate ) within 30 day of study entry.
  • History of urinary retention or lower urinary tract (bladder) stones within 6 months of study entry.
  • History of urethral obstruction due to stricture, valves, sclerosis, or tumor.
  • Current neurologic disease or condition associated with neurogenic bladder (for example, Parkinson's disease, multiple sclerosis) at study entry.
  • Clinical evidence of prostate cancer.
  • Clinical evidence of any of the following bladder conditions:

    • Mullerian duct cysts.
    • Atonic, decompensated, or hypocontractile bladder.
    • Detrusor-sphincter dyssynergia (contraction of the detrusor without sphincter relaxation).
    • Intravesical obstruction (for example, intravesical median lobe of the prostate).
    • Interstitial cystitis.
  • Clinical evidence of any of the following urinary tract conditions at study entry:

    • Urinary tract infection.
    • Urinary tract inflammation (including prostatitis). Urinary tract infection/inflammation is defined as a positive result for leukocyte esterase from a urine dipstick or >5 white blood cells (WBCs) per high-powered field on urinalysis from a centrifuged, clean-catch, midstream urine specimen.
    • Current antibiotic therapy for urinary tract infection.
    • microscopic hematuria as determined by an urologist.
  • History of significant renal insufficiency, defined as receiving renal dialysis or having an estimated \<30 milliliters per minute (mL/min) at study entry, as calculated by the central laboratory using the Cockcroft-Gault formula.
  • Clinical evidence of severe hepatic impairment [ (AST) or alanine transaminase (ALT) >3-fold of the ] at study entry.
  • History of any of the following cardiac conditions (checked at study entry):

    • Angina requiring treatment with long-acting nitrates.
    • Angina requiring treatment with short-acting nitrates within 90 days of study entry.
    • Unstable angina within 90 days of study entry.
    • Positive cardiac stress test without documented evidence of subsequent, effective cardiac intervention.
  • History of any of the following coronary conditions within 90 days of study entry:

    • Myocardial infarction.
    • Coronary artery bypass graft surgery.
    • Percutaneous coronary intervention (for example, angioplasty or stent placement).
  • Any evidence of heart disease [ (NYHA) ≥Class III] within 6 months of study entry.
  • Systolic blood pressure >160 or \<90 millimeters of mercury (mm Hg) or diastolic blood pressure >100 or \<50 mm Hg at study entry (if stress is suspected, retest under basal conditions), or malignant hypertension.
  • Glycosylated () >9% at study entry.
  • Scheduled or planned surgery (or any procedure requiring general, spinal, or epidural anesthesia) during the course of the study.
  • History of significant central nervous system injuries (including stroke or spinal cord injury) within 6 months of study entry.
  • History of drug, alcohol, or substance abuse within 6 months of study entry.
  • Current treatment with nitrates, androgens, antiandrogens, estrogens, luteinizing hormone-releasing hormone agonists/antagonists, or anabolic steroids at study entry.
  • Current systemic treatment with any of the following:

    • Potent cytochrome P450 3A4 () inhibitors, such as ketoconazole or ritonavir.
    • CYP3A4 inducers such as rifampicin.
  • Known or suspected to be hypersensitive to tadalafil, or any study drug components.
  • Any conditions that would interfere with a participant's ability to provide or comply with study instructions, would place participant at increased risk, or might confound the interpretation of the study results.
  • Previously completed or withdrawn from this study or any other study investigating tadalafil.
  • Received treatment within the last 30 days with a drug or device that has not received regulatory approval for any indications at the time of informed consent. Participants who have been screen failures in previous studies may be eligible.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
610 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Following the 4-week placebo lead-in period, this arm will consist of a 12-week placebo treatment period involving 2 x 2.5-milligram (mg) tadalafil placebo tablets taken orally once daily.

    Drug: Placebo

  • Experimental
    Tadalafil

    Following the 4-week placebo lead-in period, this arm will consist of a 12-week treatment period involving 2 x 2.5-mg tadalafil tablets taken orally once daily.

    Drug: Tadalafil · Drug: Placebo

Interventions

  • 5 mg (2 x 2.5-mg tablets), given once daily as oral tablet

    Also known as: Cialis, LY450190

  • DrugPlacebo

    2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Score of International Prostate Symptom Score (IPSS) at 12 Weeks

    The IPSS Total Score was the sum of Questions 1 through 7 in the IPSS questionnaire. Each question was based on the participant's urination experiences and prostate symptoms during the last month. Scores ranged from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score that ranged from 0 to 35; higher numerical scores represented a greater severity of symptoms. Least squares (LS) mean was based on the mixed-effect model repeated measures (MMRM) model analysis with participants as random effects, treatment, prior alpha-blocker use (yes/no), country (Japan/Korea), visit, and treatment-by-visit interaction as fixed effects, and baseline value and placebo lead-in total IPSS change as fixed covariates.

    Time frame: Baseline, 12 weeks

Secondary outcomes

  1. Change From Baseline in Total Score of International Prostate Symptom Score (IPSS)

    The IPSS Total Score was the sum of Questions 1 through 7 in the IPSS questionnaire. Each question was based on the participant's urination experiences and prostate symptoms during the last month. Scores ranged from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score that ranged from 0 to 35; higher numerical scores represented a greater severity of symptoms. Least squares (LS) mean was based on the mixed-effect model repeated measures (MMRM) model analysis with participants as random effects, treatment, prior alpha-blocker use (yes/no), country (Japan/Korea), visit, and treatment-by-visit interaction as fixed effects, and baseline value and placebo lead-in total IPSS change as fixed covariates.

    Time frame: Baseline, 4 weeks, 8 weeks

  2. Change From Baseline in the International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore

    The IPSS Storage (Irritative) Subscore was the sum of Questions 2, 4, and 7 in the IPSS questionnaire. Each question was scored from 0 (no irritative symptoms) to 5 (frequent irritative symptoms) for an IPSS Storage (Irritative) Subscore that ranged from 0 to 15; higher numerical scores represented a greater severity of symptoms. Least squares (LS) mean was based on the mixed-effect model repeated measures (MMRM) model analysis with participants as random effects, treatment, prior alpha-blocker use (yes/no), country (Japan/Korea), visit, and treatment-by-visit interaction as fixed effects, and baseline value and placebo lead-in total IPSS change as fixed covariates.

    Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks

  3. Change From Baseline in the International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore

    The IPSS Voiding (Obstructive) Subscore was the sum of Questions 1, 3, 5, and 6 in the IPSS questionnaire. Each question was scored from 0 (no obstructive symptoms) to 5 (frequent obstructive symptoms) for an IPSS Voiding (Obstructive) Subscore that ranged from 0 to 20; higher numerical scores represented a greater severity of symptoms. Least squares (LS) mean was based on the mixed-effect model repeated measures (MMRM) model analysis with participants as random effects, treatment, prior alpha-blocker use (yes/no), country (Japan/Korea), visit, and treatment-by-visit interaction as fixed effects, and baseline value and placebo lead-in total IPSS change as fixed covariates.

    Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks

  4. Change From Baseline in the International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index

    The IPSS QoL Index assessed the participant's response to the following question, "If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?". Response options were 0 (Delighted), 1 (Pleased), 2 (Mostly satisfied), 3 (Mixed, about equally satisfied and dissatisfied), 4 (Mostly dissatisfied), 5 (Unhappy), and 6 (Terrible), for a QoL Index Score that ranged from 0 to 6. Least squares (LS) mean was based on the mixed-effect model repeated measures (MMRM) model analysis with participants as random effects, treatment, prior alpha-blocker use (yes/no), country (Japan/Korea), visit, and treatment-by-visit interaction as fixed effects, and baseline value and placebo lead-in total IPSS change as fixed covariates.

    Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks

  5. Patient Global Impression of Improvement (PGI-I) Scale at 12 Weeks

    The PGI-I scale measured the participant's perception of improvement at the time of assessment compared with the start of treatment. Scores were 1 (Very much better), 2 (Much improved), 3 (Minimally improved), 4 (No change), 5 (Minimally worse), 6 (Much worse), and 7 (Very much worse).

    Time frame: 12 Weeks

  6. Clinician Global Impression of Improvement (CGI-I) Scale at 12 Weeks

    The CGI-I measured the clinician's perception of participant improvement at the time of assessment compared with the start of treatment. Scores were 1 (Very much better), 2 (Much improved), 3 (Minimally improved), 4 (No change), 5 (Minimally worse), 6 (Much worse), and 7 (Very much worse).

    Time frame: 12 Weeks

  7. Change From Baseline in Modified International Prostate Symptom Score (mIPSS) Score at 2 Weeks

    The mIPSS Total Score was the sum of Questions 1 through 7 in the mIPSS questionnaire, which was a modified version of the IPSS questionnaire. Questions about the participant's urination experiences and prostate symptoms in the IPSS questionnaire were modified to obtain responses based on time since the last visit rather than during the last month. Each question was scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an mIPSS Total Score that ranged from 0 to 35; higher numerical scores represented a greater severity of symptoms. Least squares (LS) mean was based on the analysis of covariance (ANCOVA) model with treatment, prior alpha-blocker use (yes/no), and country (Japan/Korea) as fixed effects, and baseline value and placebo lead-in total IPSS change as fixed covariates.

    Time frame: Baseline, 2 weeks

07

Results

Posted Sep 25, 2013

Participant flow

Participant flow — Overall Study
MilestonePlaceboTadalafil
Started304306
Received at least 1 dose of study drug304306
Completed293292
Not completed1114
Withdrew: Adverse event54
Withdrew: Lost to follow-up12
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject34
Withdrew: Physician decision13
Withdrew: Lack of efficacy10

Outcome measures

PrimaryChange From Baseline in Total Score of International Prostate Symptom Score (IPSS) at 12 Weeks

The IPSS Total Score was the sum of Questions 1 through 7 in the IPSS questionnaire. Each question was based on the participant's urination experiences and prostate symptoms during the last month. Scores ranged from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score that ranged from 0 to 35; higher numerical scores represented a greater severity of symptoms. Least squares (LS) mean was based on the mixed-effect model repeated measures (MMRM) model analysis with participants as random effects, treatment, prior alpha-blocker use (yes/no), country (Japan/Korea), visit, and treatment-by-visit interaction as fixed effects, and baseline value and placebo lead-in total IPSS change as fixed covariates.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Total Score of International Prostate Symptom Score (IPSS) at 12 Weeks
units on a scalePlaceboTadalafil
Change From Baseline in Total Score of International Prostate Symptom Score (IPSS) at 12 Weeks-4.5 ± 0.4-6.0 ± 0.4
Statistical analysis
  • Placebo vs Tadalafil · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -1.5 · 95% CI -2.4 to -0.6
SecondaryChange From Baseline in Total Score of International Prostate Symptom Score (IPSS)

The IPSS Total Score was the sum of Questions 1 through 7 in the IPSS questionnaire. Each question was based on the participant's urination experiences and prostate symptoms during the last month. Scores ranged from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score that ranged from 0 to 35; higher numerical scores represented a greater severity of symptoms. Least squares (LS) mean was based on the mixed-effect model repeated measures (MMRM) model analysis with participants as random effects, treatment, prior alpha-blocker use (yes/no), country (Japan/Korea), visit, and treatment-by-visit interaction as fixed effects, and baseline value and placebo lead-in total IPSS change as fixed covariates.

Time frame:
Baseline, 4 weeks, 8 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Total Score of International Prostate Symptom Score (IPSS)
units on a scalePlaceboTadalafil
Change at Week 4-2.8 ± 0.3-4.0 ± 0.4
Change at Week 8-4.0 ± 0.4-5.2 ± 0.4
Statistical analysis
  • Placebo vs Tadalafil · Mixed Models Analysis · p = <0.001 (The p-value is for the change from baseline in the IPSS Total Score at Week 4.) · Mean difference (final values): -1.3 · 95% CI -2.0 to -0.5
  • Placebo vs Tadalafil · Mixed Models Analysis · p = 0.003 (The p-value is for the change from baseline in the IPSS Total Score at Week 8.) · Mean difference (final values): -1.2 · 95% CI -2.0 to -0.4
SecondaryChange From Baseline in the International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore

The IPSS Storage (Irritative) Subscore was the sum of Questions 2, 4, and 7 in the IPSS questionnaire. Each question was scored from 0 (no irritative symptoms) to 5 (frequent irritative symptoms) for an IPSS Storage (Irritative) Subscore that ranged from 0 to 15; higher numerical scores represented a greater severity of symptoms. Least squares (LS) mean was based on the mixed-effect model repeated measures (MMRM) model analysis with participants as random effects, treatment, prior alpha-blocker use (yes/no), country (Japan/Korea), visit, and treatment-by-visit interaction as fixed effects, and baseline value and placebo lead-in total IPSS change as fixed covariates.

Time frame:
Baseline, 4 weeks, 8 weeks, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in the International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore
units on a scalePlaceboTadalafil
Change at 4 Weeks-0.9 ± 0.1-1.2 ± 0.2
Change at 8 Weeks-1.3 ± 0.2-1.7 ± 0.2
Change at 12 Weeks-1.4 ± 0.2-2.0 ± 0.2
Statistical analysis
  • Placebo vs Tadalafil · Mixed Models Analysis · p = 0.090 (The p-value was for the change from baseline in the IPSS Storage (Irritative) Subscore at Week 4.) · Mean difference (final values): -0.3 · 95% CI -0.6 to 0.0
  • Placebo vs Tadalafil · Mixed Models Analysis · p = 0.011 (The p-value was for the change from baseline in the IPSS Storage (Irritative) Subscore at Week 8.) · Mean difference (final values): -0.4 · 95% CI -0.8 to -0.1
  • Placebo vs Tadalafil · Mixed Models Analysis · p = 0.002 (The p-value was for the change from baseline in the IPSS Storage (Irritative) Subscore at Week 12.) · Mean difference (final values): -0.6 · 95% CI -0.9 to -0.2
SecondaryChange From Baseline in the International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore

The IPSS Voiding (Obstructive) Subscore was the sum of Questions 1, 3, 5, and 6 in the IPSS questionnaire. Each question was scored from 0 (no obstructive symptoms) to 5 (frequent obstructive symptoms) for an IPSS Voiding (Obstructive) Subscore that ranged from 0 to 20; higher numerical scores represented a greater severity of symptoms. Least squares (LS) mean was based on the mixed-effect model repeated measures (MMRM) model analysis with participants as random effects, treatment, prior alpha-blocker use (yes/no), country (Japan/Korea), visit, and treatment-by-visit interaction as fixed effects, and baseline value and placebo lead-in total IPSS change as fixed covariates.

Time frame:
Baseline, 4 weeks, 8 weeks, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in the International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore
units on a scalePlaceboTadalafil
Change at Week 4-1.8 ± 0.2-2.8 ± 0.2
Change at Week 8-2.6 ± 0.3-3.4 ± 0.3
Change at Week 12-3.1 ± 0.3-4.0 ± 0.3
Statistical analysis
  • Placebo vs Tadalafil · Mixed Models Analysis · p = <0.001 (The p-value was for the change from baseline in the IPSS Voiding (Obstructive) Subscore at Week 4.) · Mean difference (final values): -1.0 · 95% CI -1.5 to -0.4
  • Placebo vs Tadalafil · Mixed Models Analysis · p = 0.007 (The p-value was for the change from baseline in the IPSS Voiding (Obstructive) Subscore at Week 8.) · Mean difference (final values): -0.8 · 95% CI -1.3 to -0.2
  • Placebo vs Tadalafil · Mixed Models Analysis · p = 0.002 (The p-value was for the change from baseline in the IPSS Voiding (Obstructive) Subscore at Week 12.) · Mean difference (final values): -0.9 · 95% CI -1.5 to -0.3
SecondaryChange From Baseline in the International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index

The IPSS QoL Index assessed the participant's response to the following question, "If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?". Response options were 0 (Delighted), 1 (Pleased), 2 (Mostly satisfied), 3 (Mixed, about equally satisfied and dissatisfied), 4 (Mostly dissatisfied), 5 (Unhappy), and 6 (Terrible), for a QoL Index Score that ranged from 0 to 6. Least squares (LS) mean was based on the mixed-effect model repeated measures (MMRM) model analysis with participants as random effects, treatment, prior alpha-blocker use (yes/no), country (Japan/Korea), visit, and treatment-by-visit interaction as fixed effects, and baseline value and placebo lead-in total IPSS change as fixed covariates.

Time frame:
Baseline, 4 weeks, 8 weeks, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in the International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index
units on a scalePlaceboTadalafil
Change at Week 4-0.5 ± 0.1-0.6 ± 0.1
Change at Week 8-0.7 ± 0.1-0.8 ± 0.1
Change at Week 12-0.9 ± 0.1-1.1 ± 0.1
Statistical analysis
  • Placebo vs Tadalafil · Mixed Models Analysis · p = 0.277 (The p-value was for the change from baseline in the IPSS QoL Index Score at Week 4.) · Mean difference (final values): -0.1 · 95% CI -0.2 to 0.1
  • Placebo vs Tadalafil · Mixed Models Analysis · p = 0.170 (The p-value was for the change from baseline in the IPSS QoL Index Score at Week 8.) · Mean difference (final values): -0.1 · 95% CI -0.3 to 0.1
  • Placebo vs Tadalafil · Mixed Models Analysis · p = 0.038 (The p-value was for the change from baseline in the IPSS QoL Index Score at Week 12.) · Mean difference (final values): -0.2 · 95% CI -0.4 to -0.0
SecondaryPatient Global Impression of Improvement (PGI-I) Scale at 12 Weeks

The PGI-I scale measured the participant's perception of improvement at the time of assessment compared with the start of treatment. Scores were 1 (Very much better), 2 (Much improved), 3 (Minimally improved), 4 (No change), 5 (Minimally worse), 6 (Much worse), and 7 (Very much worse).

Time frame:
12 Weeks
Reported as:
Number · participants
Patient Global Impression of Improvement (PGI-I) Scale at 12 Weeks
participantsPlaceboTadalafil
Very Much Better918
Much Better5579
A Little Better138148
No Change9055
A Little Worse72
Much Worse00
Very Much Worse20
Missing34
Statistical analysis
  • Placebo vs Tadalafil · Cochran-Mantel-Haenszel · p = <0.001 (The p-value was from the Cochran-Mantel-Haenszel test adjusted for baseline severity of benign prostatic hyperplasia lower urinary tract symptoms (BPH-LUTS) and previous alpha-blocker therapy.)
SecondaryClinician Global Impression of Improvement (CGI-I) Scale at 12 Weeks

The CGI-I measured the clinician's perception of participant improvement at the time of assessment compared with the start of treatment. Scores were 1 (Very much better), 2 (Much improved), 3 (Minimally improved), 4 (No change), 5 (Minimally worse), 6 (Much worse), and 7 (Very much worse).

Time frame:
12 Weeks
Reported as:
Number · participants
Clinician Global Impression of Improvement (CGI-I) Scale at 12 Weeks
participantsPlaceboTadalafil
Very Much Improved1014
Much Improved74103
Minimally Improved115125
No Change9359
Minimally Worse81
Much Worse00
Very Much Worse10
Missing34
Statistical analysis
  • Placebo vs Tadalafil · Cochran-Mantel-Haenszel · p = <0.001 (The p-value was from the Cochran-Mantel-Haenszel test adjusted for baseline severity of benign prostatic hyperplasia lower urinary tract symptoms (BPH-LUTS) and previous alpha-blocker therapy.)
SecondaryChange From Baseline in Modified International Prostate Symptom Score (mIPSS) Score at 2 Weeks

The mIPSS Total Score was the sum of Questions 1 through 7 in the mIPSS questionnaire, which was a modified version of the IPSS questionnaire. Questions about the participant's urination experiences and prostate symptoms in the IPSS questionnaire were modified to obtain responses based on time since the last visit rather than during the last month. Each question was scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an mIPSS Total Score that ranged from 0 to 35; higher numerical scores represented a greater severity of symptoms. Least squares (LS) mean was based on the analysis of covariance (ANCOVA) model with treatment, prior alpha-blocker use (yes/no), and country (Japan/Korea) as fixed effects, and baseline value and placebo lead-in total IPSS change as fixed covariates.

Time frame:
Baseline, 2 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Modified International Prostate Symptom Score (mIPSS) Score at 2 Weeks
units on a scalePlaceboTadalafil
Change From Baseline in Modified International Prostate Symptom Score (mIPSS) Score at 2 Weeks-2.1 ± 0.3-2.7 ± 0.3
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = 0.060 · Mean difference (final values): -0.6 · 95% CI -1.2 to 0.0

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/304 (0.3%)75/304 (24.7%)
Tadalafil—2/306 (0.7%)87/306 (28.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboTadalafil
Cardio-respiratory arrestCardiac disorders1/3040/306
Spinal cord injury cervicalInjury, poisoning and procedural complications1/3040/306
CholecystitisHepatobiliary disorders0/3041/306
Back painMusculoskeletal and connective tissue disorders0/3041/306
Most frequent other events
Showing 10 of 107
Most frequent other events
EventPlaceboTadalafil
NasopharyngitisInfections and infestations10/30413/306
DyspepsiaGastrointestinal disorders2/30412/306
HeadacheNervous system disorders6/3049/306
Blood creatine phosphokinase increasedInvestigations7/3047/306
Aspartate aminotransferase increasedInvestigations6/3041/306
Upper respiratory tract infectionInfections and infestations5/3042/306
DiarrhoeaGastrointestinal disorders1/3045/306
Alanine aminotransferase increasedInvestigations4/3040/306
Creatinine renal clearance decreasedInvestigations1/3044/306
Back painMusculoskeletal and connective tissue disorders3/3044/306

Baseline characteristics

All randomized participants.

Age Continuous
Age Continuous(years)PlaceboTadalafilTotal
Mean60.9 ± 8.160.8 ± 7.760.9 ± 7.9
Age, Customized
Age, Customized(participants)PlaceboTadalafilTotal
<65 years201198399
>=65 years103108211
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTadalafilTotal
Female000
Male304306610
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboTadalafilTotal
Asian304306610
Region of Enrollment
Region of Enrollment(participants)PlaceboTadalafilTotal
Japan222227449
Korea, Republic of8279161
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per square meter (kg/m^2))PlaceboTadalafilTotal
Mean24.1 ± 2.924.0 ± 3.024.0 ± 3.0
Current Tobacco Use
Current Tobacco Use(participants)PlaceboTadalafilTotal
Yes5557112
No249249498
Alcohol Use
Alcohol Use(participants)PlaceboTadalafilTotal
Yes196206402
No108100208

8 further baseline measures are reported on the registry.

08

Study locations

17 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 270-0034, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ehime, 790-0962, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 816-0943, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyogo, 650-0012, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kagoshima, 891-0105, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 252-0143, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kyoto, 600-8813, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 553-0001, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saitama, 331-0823, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 150-0002, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yamanashi, 407-0015, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Goyang-Si, 412-270, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Incheon, 400-711, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jeon Ju-City, 561-712, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kwang Ju, 501-757, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pusan, 609 735, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 137-040, Korea, Republic of
09

References and documents

Publications

  • Takeda M, Yokoyama O, Lee SW, Murakami M, Morisaki Y, Viktrup L. Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea. Int J Urol. 2014 Jul;21(7):670-5. doi: 10.1111/iju.12410. Epub 2014 Feb 27. PubMed 24571205 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2011
First posted
Oct 26, 2011
Start
Dec 2011
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
Sep 25, 2013
Last update
Sep 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01460342
Responsible party
Sponsor
First posted
Oct 26, 2011
Start date
Dec 2011
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Sep 25, 2013
Last update
Sep 25, 2013

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion